Cited by 690Cancer Genomics and DiagnosticsColorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

The DOI matches its Crossref record; 23 of the 28 references it cites were found in a registry or an index.

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

Open access

Tie, Jeanne, Cohen, Joshua D., Wang, Yuxuan, Christie, Michael, Simons, Koen, Lee, Margaret, Wong, Rachel, Kosmider, Suzanne, Ananda, Sumitra, McKendrick, Joseph, Lee, Belinda, Cho, Jin Hee, Faragher, Ian, Jones, Ian T., Ptak, Janine, Schaeffer, Mary J., Silliman, Natalie, Dobbyn, Lisa, Li, Lu, Tomasetti, Cristian, Papadopoulos, Nicholas, Kinzler, Kenneth W., Vogelstein, Bert, Gibbs, Peter·2019·JAMA Oncology

DOI 10.1001/jamaoncol.2019.3616PMC PMC6802034

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Adjuvant chemotherapy in patients with stage III colon cancer prevents recurrence by eradicating minimal residual disease. However, which patients remain at high risk of recurrence after completing standard adjuvant treatment cannot currently be determined. Postsurgical circulating tumor DNA (ctDNA) analysis can detect minimal residual disease and is associated with recurrence in colorectal cancers. Objective: To determine whether serial postsurgical and postchemotherapy ctDNA analysis could provide a real-time indication of adjuvant therapy efficacy in stage III colon cancer. Design, Setting, and Participants: This multicenter, Australian, population-based cohort biomarker study recruited 100 consecutive patients with newly diagnosed stage III colon cancer planned for 24 weeks of adjuvant chemotherapy from November 1, 2014, through May 31, 2017. Patients with another malignant neoplasm diagnosed within the last 3 years were excluded. Median duration of follow-up was 28.9 months (range, 11.6-46.4 months). Physicians were blinded to ctDNA results. Data were analyzed from December 10, 2018, through June 23, 2019. Exposures: Serial plasma samples were collected after surgery and after chemotherapy. Somatic mutations in individual patients' tumors were identified via massively parallel sequencing of 15 genes commonly mutated in colorectal cancer. Personalized assays were designed to quantify ctDNA. Main Outcomes and Measures: Detection of ctDNA and recurrence-free interval (RFI). Results: After 4 exclusions, 96 eligible patients were eligible; median patient age was 64 years (range, 26-82 years); 49 (51%) were men. At least 1 somatic mutation was identified in the tumor tissue of all 96 evaluable patients. Circulating tumor DNA was detectable in 20 of 96 (21%) postsurgical samples and was associated with inferior recurrence-free survival (hazard ratio [HR], 3.8; 95% CI, 2.4-21.0; P < .001). Circulating tumor DNA was detectable in 15 of 88 (17%) postchemotherapy samples. The estimated 3-year RFI was 30% when ctDNA was detectable after chemotherapy and 77% when ctDNA was undetectable (HR, 6.8; 95% CI, 11.0-157.0; P < .001). Postsurgical ctDNA status remained independently associated with RFI after adjusting for known clinicopathologic risk factors (HR, 7.5; 95% CI, 3.5-16.1; P < .001). Conclusions and Relevance: Results suggest that ctDNA analysis after surgery is a promising prognostic marker in stage III colon cancer. Postchemotherapy ctDNA analysis may define a patient subset that remains at high risk of recurrence despite completing standard adjuvant treatment. This high-risk population presents a unique opportunity to explore additional therapeutic approaches.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2019.3616

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Self-citation
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,261
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Self-citation
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
García-Murillas, I., Schiavon, G., Weigelt, B., Ng, C. K. Y., Hrebien, S., Cutts, R. J., Cheang, M. C. U., Osin, P., Nerurkar, A. Y., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,174
Detection and quantification of rare mutations with massively parallel sequencing
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105422108 · Cited by 1,144
Self-citation
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,105

Show all 28 references

Research works printed but not linked: 1

Song, 2008, A semiparametric approach for the covariate specific ROC curve with survival outcome., Stat Sin, 947

Sorted by citations

Items 501–600 of 690

Circulating Tumor DNA as a Biomarker for Recurrence After Curative Resection of Colorectal Cancer Liver Metastases: A Systematic Review and Meta-Analysis
Khan, A. U., Mehboob, A. A., Yousif, A. A., Ali, A., & Kadham, M. J. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.01.006 · Cited by 1
Molecular residual disease assessment in colorectal and bladder cancer by somatic structural variant analysis of cell-free DNA whole-genome sequencing data
Sørensen, E. E., Frydendahl, A., Rasmussen, M. H., Nordentoft, I., Knudsen, M., Henriksen, T. V., Lindskrog, S. V., Dyrskjøt, L., Andersen, C. L., & Bramsen, J. B. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07762-6 · Cited by 1
Oncogenicity and Therapeutic Implications of Molecular Biomarkers in Colorectal Carcinoma
Evans, M. G., & Hechtman, J. F. (2026) · Surgical pathology clinics · doi:10.1016/j.path.2026.01.010 · Cited by 1
Real‑World Experience of Circulating Tumor DNA Testing in Extended Pelvic Exenteration: A Chinese Single‑Institution Observational Study
Lu, Y., Chen, J. N., Chen, G., Peng, H., & Zhang, J. (2026) · Journal of Surgical Oncology · doi:10.1002/jso.70294 · Cited by 1
Peritoneal Metastases in Stage II–III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance
Ofori, K. A., Smart, H., Liu, S., Bader, J. M., Aguirre, N., Gupta, P., Sharma, A. R., & Turaga, K. K. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19903-8 · Cited by 1
Circulating tumor DNA in gastrointestinal cancers: promise, pitfalls, and the path forward
Mukherjee, S., Sarfraz, A., Aung, K. L., & Ahluwalia, M. S. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104122 · Cited by 1
Postoperative ctDNA-Guided Adjuvant Therapy in Resected Colorectal Cancer: A Systematic Review and Meta-analysis of Prognostic Validity Versus Treatment-Decision Utility
韩, 峥., Zhang, Y., Tian, Q., Zhu, H., Wang, H., & Li, C. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01578-9 · Cited by 1
[MinerVa: A high performance bioinformatic algorithm for the detection of minimal residual disease in solid tumors].
Yang, P., Zhang, Y., Xia, L., Mei, J., Fan, R., Huang, Y. S., Liu, L., & Chen, W. (2023) · PubMed Central · doi:10.7507/1001-5515.202303039 · Cited by 1
Sensitive and Specific Analyses of Colorectal Cancer Recurrence through Multiplex superRCA Mutation Detection in Blood Plasma
Sandberg, E., Nunes, L., Edqvist, P.-H. D., Mathot, L., Chen, L., Edgren, T., Nassralla, S. A., Glimelius, B. L. G., Landegren, U. D., & Sjöblom, T. (2024) · Cancers · doi:10.3390/cancers16030549 · Cited by 1
Clinical insights into circulating free-DNA in patients with bone sarcomas and ewing sarcoma
Aran, V., Cavalcanti, A. D. S., Meohas, W., Delocco, B. C., Perini, J. A., Pino, J., Guimaräes, J. A. M., Moura‐Neto, V., & Duarte, M. E. L. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100661 · Cited by 1
Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts
Aref, A. T., Pathan, M., Habib, R., Hains, P. G., Lim, S. H.-S., Anees, A., Ma, L., Heads, J. A., Wang, D., Loudon, C., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3200 · Cited by 1
New Compass for Precision Oncology: Evidence, Challenges, and Prospects of Circulating Tumor DNA in Colorectal Cancer
Suzuki, K., Ooki, A., Shinozaki, E., Toyokawa, E., Yoshikawa, K., Shiozawa, M., Maeda, S., Yamaguchi, K., & Osumi, H. (2026) · Cancer Control · doi:10.1177/10732748261458456 · Cited by 1
The role of circulating tumor DNA in ovarian cancer
Abulajiang, Y., Ming, W., & Wu, Y. (2026) · Discover Oncology · doi:10.1007/s12672-026-05333-1 · Cited by 1
Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial
Subramanian, A., Nouth, S. C. L., Nemat‐Gorgani, N., Soudi, S., Ballman, K. V., Heise, R. S., Johns, C., Sears, T. J., Roohani, S., Krcek, R., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00769 · Cited by 1
Circulating Tumor DNA in Cancer Management: A Value Proposition
Lam, W. K. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa112 · Cited by 1
Metagenomics from bench to bedside and from bedside to bench
Jia, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91369-0.00006-6 · Cited by 1
Real‐world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer
To, Y. H., Degeling, K., McCoy, M. J., Wong, R., Jones, I. T., Dunn, C., Hong, W., Loft, M., Gibbs, P., & Tie, J. (2022) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13885 · Cited by 1
Self-citation
Therapiemonitoring der neoadjuvanten Radio‑/Chemotherapie
Holzgreve, A., Mäurer, M. A., Gassert, F. T., Oing, C., Sulzer, S., Ziegler, S., Staudacher, J. J., Peuker, C.-A., Unterrainer, L. M., Fabritius, M. P., et al. (2023) · Die Onkologie · doi:10.1007/s00761-023-01387-w · Cited by 1
[Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors].
Chen, Y. (2023) · PubMed Central · doi:10.7499/j.issn.1008-8830.2304040 · Cited by 1
Individualization of adjuvant therapy: who can I refuse?
Карабина, Е. В. (2023) · Practical oncology · doi:10.31917/2404319 · Cited by 1
State of the art: Targeting microsatellite instability in gastrointestinal cancers
Mencel, J., Alves, A., Angelis, V., Gerlinger, M., & Starling, N. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104387 · Cited by 1
Combining Circulating Tumour DNA with Clinical Pathological Risk Factors for Developing Peritoneal Metastasis Prediction Model in Patients with Colorectal Cancer
Han, B., Hu, H., Zhang, J., Xie, X., & Deng, Y. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0704 · Cited by 1
Site‐Specific Mutations on KRAS , NRAS , and BRAF Corelate With the Frequency of ctDNA in Colorectal Cancer
Yoshimura, F., Yoshida, Y., Yamada, T., Tanaka, K., Hayashi, T., Shimaoka, H., Sakamoto, R., Aisu, N., Yoshimatsu, G., Hasegawa, S., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70292 · Cited by 1
Circulating tumour DNA-guided adjuvant chemotherapy in colorectal carcinoma
Reichinger, A., & Rumpold, H. (2020) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-020-00607-y · Cited by 1
The Revolution of Liquid Biopsy and Single-Cell Sequencing in the Management of Colorectal Cancer
Bairi, K. E., Trapani, D., & Amrani, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-53821-7_6 · Cited by 1
Clinical relevance of circulating tumour DNA in colorectal cancer
Kong, J. C. H., Prabhakaran, S., Tie, J., Ramsay, R. G., Heriot, A. G., & Warrier, S. K. (2021) · ANZ Journal of Surgery · doi:10.1111/ans.16419 · Cited by 1
Self-citation
Cutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma
Lee, C. M. L., Zwerner, J. P., O’Brian, B., & Eng, C. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.09.010 · Cited by 1
Time for a lead-time definition? Author response to ‘Why the length of recurrence free survival or “lead-times” can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis’
Spindler, K. G., Callesen, L. B., & Arnold, D. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231156393 · Cited by 1
Epigenetic Alterations in Colorectal Cancer
Ko, B., Hanna, M., Yu, M., & Grady, W. M. (2023) · Epigenetics and human health · doi:10.1007/978-3-031-42365-9_10 · Cited by 1
High throughput sequencing technology and its clinical application in circulating tumor DNA detection in patients with tumors.
Xu, C., Zhou, D., & Zhu, M. (2024) · Investigación Clínica · doi:10.54817/ic.v65n4a09 · Cited by 1
Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer—Reply
Tie, J., Vogelstein, B., & Gibbs, P. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0289 · Cited by 1
Self-citation
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer (DYNAMIC Trial): Statistical Analysis PlanPreprint
Tie, J., Lo, S., Cohen, J. D., Wang, Y., Wong, R., Shapiro, J. D., Harris, S., Khattak, A., Burge, M., Vogelstein, B., et al. (2021) · medRxiv · doi:10.1101/2021.09.02.21262816 · Cited by 1
Self-citation
Error in Figure 2D
(2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5667 · Cited by 1
Utility of circulating tumor DNA in patients undergoing hepatectomy for colorectal liver metastases
Cnockaert, P., Muscari, F., & Maulat, C. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-310 · Cited by 1
Biomarker-Guided Adjuvant Therapy in Stage II/III Colon Cancer: A Systematic Review of Current Evidence and Clinical Implications
Ismaili, N. (2026) · Cancer Investigation · doi:10.1080/07357907.2026.2696794 · Cited by 1
Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study
Roberts, H. J., Comeau, H., Klega, K., DuBois, S. G., Lazo de la Vega, L., Ceca, E., Mullen, E. A., Smith, G. A., Tukachinsky, H., Huang, R. S. P., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01125
Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much better
Sclafani, F., & Hendlisz, A. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000638
Adjuvante Therapie des kolorektalen Karzinoms
Kraeft, A., Reinacher-Schick, A. C., & Folprecht, G. (2020) · Die Gastroenterologie · doi:10.1007/s11377-020-00453-8
Detection of Circulating Tumor DNA in Solid Tumors
Testa, U., Castelli, G., & Pelosi, E. (2020) · OBM Genetics · doi:10.21926/obm.genet.2003114
Adjuvant Therapies in Colon Cancer
Prasanna, T., & Yip, D. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.93874
(Neo)adjuvante Behandlung beim frühen Kolonkarzinom
Kraeft, A., Stein, A., Modest, D. P., Fichtner‐Feigl, S., Tannapfel, A., & Reinacher‐Schick, A. (2020) · Der Onkologe · doi:10.1007/s00761-020-00876-6
Clonal Hematopoiesis in Lung Cancer and Its Impact on Liquid Biopsy Based on Targeted Deep SequencingPreprint
Xue, Y., Wang, Y., Li, Y., Liu, D., Shao, M., Liu, L., Liao, Y., Huang, T., Zhang, J., Mu, T., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-907910/v1
Self-citation
Systemic treatment of localized colorectal cancer
Hans, D., Vandamme, T., Teuwen, L.-A. M. N., Laura, W., Prenen, H., ten Tije, Jan, A., & Marc, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824297-1.00017-8
Intervenciones de enfermería en pacientes con colostomía
Segovia-Monga, M. C., Guamushig-Tipan, A. E., Moreta-Moreta, K. J., & Martínez, N. G. (2022) · Revista Arbitrada Interdisciplinaria de Ciencias de la Salud Salud y Vida · doi:10.35381/s.v.v6i1.1691
Integration of microfluidics with biosensing technology for noncommunicable disease diagnosis
Lim, S. A., Ahmad, A. N., Rosli, R., & Safar, S. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85147-3.00012-8
Use of Circulating Tumour DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers
Mukherji, R., Alqahtani, A. J., Winters, H. D., & Weinberg, B. A. (2022) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2022.18.1.26
Prognostische und prädiktive Biomarker beim kolorektalen Karzinom
Stintzing, S., & Jelas, I. (2022) · Trillium Diagnostik · doi:10.47184/td.2022.03.03
Circulating Tumour DNA and Risk-Stratified Surveillance Strategies for Patients with Colorectal Liver Metastases
Newhook, T. E., & Kawaguchi, Y. (2022) · Springer eBooks · doi:10.1007/978-3-031-09323-4_59
Adjuvant Systemic Chemotherapy
Morris, V. K. (2022) · Springer eBooks · doi:10.1007/978-3-031-09323-4_34
Circulating Tumor DNA-Guided Minimal Residual Disease Assessment in Colorectal Cancer
Chakrabarti, S., & Mahipal, A. (2023) · Pharmacogenomics · doi:10.2217/pgs-2022-0170
Data from Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
Parikh, A. R., Seventer, E. E. V., Siravegna, G., Hartwig, A. V., Jaimovich, A., He, Y., Kanter, K. N., Fish, M. G., Fosbenner, K. D., Miao, B., et al. (2023) · doi:10.1158/1078-0432.c.6530634
Data from Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
Parikh, A. R., Seventer, E. E. V., Siravegna, G., Hartwig, A. V., Jaimovich, A., He, Y., Kanter, K. N., Fish, M. G., Fosbenner, K. D., Miao, B., et al. (2023) · doi:10.1158/1078-0432.c.6530634.v1
Supplementary Figure 1 from Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial
Vidal, J., Casadevall, D., Bellosillo, B., Pericay, C., García‐Carbonero, R., Losa, F., Layos, L., Alonso, V., Capdevila, J., Gallego-Plazas, J., et al. (2023) · doi:10.1158/1078-0432.22479621
Data from Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence
Xie, H., Mahoney, D. W., Foote, P. H., Burger, K. N., Doering, K. A., Taylor, W. R., Then, S. S., Cao, X., McGlinch, M. C., Berger, C. K., et al. (2023) · doi:10.1158/1078-0432.c.6529932
Data from Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial
Vidal, J., Casadevall, D., Bellosillo, B., Pericay, C., García‐Carbonero, R., Losa, F., Layos, L., Alonso, V., Capdevila, J., Gallego-Plazas, J., et al. (2023) · doi:10.1158/1078-0432.c.6530259
Data from Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial
Vidal, J., Casadevall, D., Bellosillo, B., Pericay, C., García‐Carbonero, R., Losa, F., Layos, L., Alonso, V., Capdevila, J., Gallego-Plazas, J., et al. (2023) · doi:10.1158/1078-0432.c.6530259.v1
Data from Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer
Morris, V. K., Overman, M. J., Lam, M., Parseghian, C. M., Johnson, B., Dasari, A. N., Raghav, K. P. S., Kee, B. K., Huey, R. W., Wolff, R. A., et al. (2023) · doi:10.1158/2767-9764.c.6550830.v1
Circulating-tumor DNA and cancer-induced gene expression as novel liquid biomarkers of liver cancers
Kunadirek, P. (2020) · Chula Digiverse · doi:10.58837/chula.the.2020.305
Progress in companion diagnosis of colorectal cancer
Su, Q. (2023) · International Journal of Biology and Life Sciences · doi:10.54097/ijbls.v2i2.7172
Recurrence monitoring using ctDNA in patients with metastasis of colorectal cancer: COSMOS- oligo studyPreprint
Oki, E., Nakanishi, R., Ando, K., Nambara, S., Takemasa, I., Watanabe, J., Matsuhashi, N., Kato, T., Kagawa, Y., Kotaka, M., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2844259/v1
The American Society of Breast Surgeons Official Proceedings, Volume XXIV 2023 Annual Meeting Scientific Session Abstracts
(2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13650-w
Analysis of the clinical value of postoperative circulating tumor DNA (ctDNA) within the first month for resected colorectal cancer in a real-world.Preprint
Feng, Z., Sun, Z., Song, Y., zhang, Y., hai, Y., Zheng, M., wu, Z., Ren, S., & Zhang, Q. (2023) · Research Square · doi:10.21203/rs.3.rs-3175058/v1
Diagnostic testing
Wolfe, A. R., Prasad, R. N., Perlow, H. K., Wang, K., Facer, B. D., & Ritter, A. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88423-5.00100-x
Delivering Data-Driven Precision and Equitable Artificial Intelligence Decision Tools in Oncology: Exploring the Informarker Concept
Lin, F. P. Y. (2023) · JCO Clinical Cancer Informatics · doi:10.1200/cci.23.00142
Additional file 9 of Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer
Chen, G., Peng, J., Xiao, Q., Wu, H., Wu, X., Wang, F., Li, L., Ding, P., Zhao, Q., Li, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14608883
Self-citation
Additional file 1 of Development and clinical validation of a novel six-gene signature for accurately predicting the recurrence risk of patients with stage II/III colorectal cancer
Liu, Z., Lu, T., Li, J., Wang, L., Xu, K., Dang, Q., Guo, C., Liu, L., Jiao, D., Sun, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14927045
Additional file 6 of Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer
Chen, G., Peng, J., Xiao, Q., Wu, H., Wu, X., Wang, F., Li, L., Ding, P., Zhao, Q., Li, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14608874
Self-citation
Additional file 7 of Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer
Chen, G., Peng, J., Xiao, Q., Wu, H., Wu, X., Wang, F., Li, L., Ding, P., Zhao, Q., Li, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14608877
Self-citation
Influences of Patient Characteristics on the Predictive Value of Molecular Biomarkers of Colon Cancer in Tubular Adenomas
Sutherland, S., Jiang, A. C., Melson, J. E., & Buckingham, L. E. (2022) · American Society for Clinical Laboratory Science · doi:10.29074/ascls.2020002790
Prognostic implications of tumor mutation burden in postoperative patients with colorectal cancer who received capecitabine-based adjuvant chemotherapy: a retrospective exploratory studyPreprint
Zhu, Y., Zhang, H., Zhou, Y., Chen, W., & Lu, D. (2024) · Research Square · doi:10.21203/rs.3.rs-4357440/v1
Role of chemotherapy in colorectal cancers
Parisier, E. L., & Ocean, A. J. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780192863584.003.0016
ctDNA Testing for Minimal Residual Disease Assessment and Surveillance
Ivatury, S. J. (2024) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000003490
Lokal begrenztes Kolonkarzinom: Adjuvante und neoadjuvante Therapie
Modest, D. P., & Stintzing, S. (2024) · Trillium Krebsmedizin · doi:10.47184/tk.2024.05.3
Application of ctDNA in Colorectal Cancer Detection
王, 明. (2024) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2024.144062
Evaluation of Circulating Tumor DNA and Carcinoembryonic Antigen Levels and Relationship with Clinicopathological Risk Factors and Prognostic Indices in Colorectal Cancer Patients
Yaslıkaya, Ş., Türker, M., Camadan, Y. A., Kıdı, M. M., Biter, S., Asarkaya, E., Asoglu, H., İpek, Ş. A., Kara, İ. O., & Şahin, B. (2024) · Scientific reports in medicine. · doi:10.37609/srinmed.20
Advances in Molecular Biology Knowledge of Rectal Cancer and Forthcoming Role of Liquid Biopsy
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5643-6
Revista Argentina de Coloproctología Relato Oficial 2024
Amarillo, H. A. (2024) · Revista Argentina de Coloproctología · doi:10.46768/racp.v35i4.326
CAPÍTULO 15 Terapia adyuvante
Amarillo, H. A. (2024) · Revista Argentina de Coloproctología · doi:10.46768/racp.v35i4.342
The role of circulating tumor cells in the immunotherapy of pancreatic and colon cancers
Srikar, A., & Dakshinamurthy, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00021-6
A Call for Improved Guidance to Integrate Modern Biomarkers Into Routine Clinical Care—Piecing the Puzzle Together
Dunn, C., Tie, J., & Gibbs, P. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.6479
Self-citation
Circulating Tumor DNA Predicts Conversion Therapy Response and Prognosis in Initially Unresectable Colorectal Liver-Limited Metastases: A Retrospective Study
Han, B., Shen, C., Hu, H., Zhang, J., Xie, X., Mo, Q., & Deng, Y. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0695
A Decade of JAMA Oncology
Disis, M. L. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.0853
Finding a needle in a haystack: Measures of circulating tumor DNA (ctDNA) to guide treatment decisions in oncology
Dubrovsky, G., Earland, N. J., Harris, P., Chauhan, P. S., Szymanski, J. J., Chaudhuri, A. A., Zevallos, J. P., & Lotze, M. T. (2025) · Methods in cell biology · doi:10.1016/bs.mcb.2025.03.022
Circulating Tumor DNA in the Surgical Management of Cancer: A Review of Clinical Trials to Understand Future Impact on Multidisciplinary Practice
Rasic, G., Alonso, A. G., Collado, L., Devaiah, A. K., & Godfrey, T. E. (2025) · The American Surgeon · doi:10.1177/00031348251346546
A Study on the Correlation between Postoperative Changes in Serum Carcinoembryonic Antigen (CEA) Levels and Prognosis in Patients with Stage II/III Colorectal Cancer after Surgery
乔, 建. (2025) · Medical Diagnosis · doi:10.12677/md.2025.153038
Circulating biomarkers: Facilitating the diagnosis and treatment of cancer and other chronic diseases
Ji, H., Ye, T., Nie, X., Chen, Y., Li, H., Chen, S., Xiao, Y., Shao, M., Wang, T., Zheng, R., et al. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2025.05.001
Intérêt de la détection de l’ADN tumoral circulant dans les cancers colorectaux en 2025
Laurent‐Puig, P. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.03.009
Integrated CT-derived radiomics for predicting ctDNA status and prognosis in resectable non-small cell lung cancerPreprint
Gong, Z., Cao, Y., Wang, X., Wang, H., Xu, J., Wang, H., Zhang, X., Gong, H., Liu, J., Yang, J., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7084858/v1
Integration of Circulating Tumor DNA into Clinical Practice for Melanoma
Harris, M. S., Steimle, A. K., & Ma, V. T.-L. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1012473
Transplant Oncology—A New Frontier in Liver Cancer Care
Yohanathan, L., & Baker, T. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18437-9
From Blood to Bedside: A Review of Liquid Biopsy for Minimal Residual Disease and Recurrence Prediction in Early-Stage Breast Cancer
Otene, S. A., Gbaa, Z., Omolabake, B. I., Tsegha, L., Onyewuchi, A. J., Ojo, B., Gbaa, A. F., & Labe, R. M. (2025) · doi:10.38124/ijisrt/25oct1032
Circulating tumor DNA as a predictor of response and prognosis in rectal cancer treated with total neoadjuvant therapy (JCOG2010A1-ctTNT study)
Hashimoto, T., Hirano, H., Takashima, A., Sekine, S., Kanato, K., Mizusawa, J., Fukuda, H., Tsukamoto, S., & Kanemitsu, Y. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100212
Prognostic significance of circulating tumor DNA in non-metastatic colorectal cancer
Li, R., Wang, S., Xu, J., Zhao, M., Zhang, H., Yin, Y., Han, X., Liu, B., & Liu, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-04171-x
Evaluation of Circulating Tumor DNA as a Biomarker for Chemoresistance in Colorectal Cancer
Lakshmi, K. R., Sankaranarayanan, C. S., Gogineni, R. A. S., Shaheen, K. A., & Peddi, P. (2025) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_1319_25
Additional file 16 of Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer
Chen, G., Peng, J., Xiao, Q., Wu, H.-X., Wu, X., Wang, F., Li, L., Ding, P., Zhao, Q., Li, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14608850
Self-citation
Additional file 8 of Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer
Chen, G., Peng, J., Xiao, Q., Wu, H.-X., Wu, X., Wang, F., Li, L., Ding, P., Zhao, Q., Li, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14608880
Self-citation
Additional file 17 of Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer
Chen, G., Peng, J., Xiao, Q., Wu, H.-X., Wu, X., Wang, F., Li, L., Ding, P., Zhao, Q., Li, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14608853
Self-citation
Additional file 5 of Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer
Chen, G., Peng, J., Xiao, Q., Wu, H.-X., Wu, X., Wang, F., Li, L., Ding, P., Zhao, Q., Li, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14608871
Self-citation
Additional file 12 of Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application
Casas-Arozamena, C., Vilar, A., Cueva, J. F., Arias, E., Sampayo, V., Díaz, E., Oltra, S. S., Moiola, C. P., Cabrera, S., Cortegoso, A., et al. (2024) · DIGITAL.CSIC (Spanish National Research Council (CSIC)) · doi:10.6084/m9.figshare.27078912
Additional file 3 of Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application
Casas-Arozamena, C., Vilar, A., Cueva, J. F., Arias, E., Sampayo, V., Díaz, E., Oltra, S. S., Moiola, C. P., Cabrera, S., Cortegoso, A., et al. (2024) · DIGITAL.CSIC (Spanish National Research Council (CSIC)) · doi:10.6084/m9.figshare.27078885

Authors: Tie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., Lee, B., Cho, J. H., Faragher, I., Jones, I. T., Ptak, J., Schaeffer, M. J., Silliman, N., Dobbyn, L., Li, L., Tomasetti, C., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Gibbs, P.
Affiliations: The University of Melbourne (AU)
Johns Hopkins University (US)
The Royal Melbourne Hospital (AU)
Walter and Eliza Hall Institute of Medical Research (AU)
Western Health (AU)
Eastern Health (AU)
Division of Biostatistics & Bioinformatics, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland
Corresponding author: Tie, Jeanne
ORCID: Tie, Jeanne
Cohen, Joshua D.
Wang, Yuxuan
Christie, Michael
Simons, Koen
Wong, Rachel
Kosmider, Suzanne
Lee, Belinda
Cho, Jin Hee
Faragher, Ian
Jones, Ian T.
Ptak, Janine
Silliman, Natalie
Dobbyn, Lisa
Tomasetti, Cristian
Kinzler, Kenneth W.
Vogelstein, Bert
Gibbs, Peter
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2019-12-01
Volume: 5
Issue: 12
Pages: 1710
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2019.3616
PMC: PMC6802034
OpenAlex: W2980567593
Cited by: 668
References: 28
Citations by year: 2026: 76 · 2025: 91 · 2024: 104 · 2023: 124 · 2022: 107 · 2021: 102 · 2020: 57 · 2019: 6
FWCI: 21.84
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P50CA062924)
National Institute of General Medical Sciences (T32GM136577)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords: circulating tumor DNA, stage III colon cancer, adjuvant chemotherapy, recurrence risk, minimal residual disease, recurrence-free interval, somatic mutations, liquid biopsy, predictive biomarkers, treatment response monitoring, recurrent colorectal cancer, recurrence-free survival, prognostic factors
MeSH terms: Circulating Tumor DNA, Adult, Aged, Aged, 80 and over, Australia, Colonic Neoplasms, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Risk Factors, Biomarkers, Tumor, Treatment Outcome, Chemotherapy, Adjuvant, Neoplasm, Residual, Disease-Free Survival, Precision Medicine, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks